PRGF exerts more potent proliferative and anti-inflammatory effects than autologous serum on a cell culture inflammatory model

Anitua, Eduardo; Muruzábal, Francisco; Fuente, María de la; Riestra, Ana Cristina; Merayo‐Lloves, Jesús; Orive, Gorka

doi:10.1016/j.exer.2016.08.012

Cited by 47 publications

(25 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a new alternative, plasma rich in growth factors (PRGF) is a hemoderivative product, which is different from AS, and has been proposed for the treatment of DED [ 8 ]. An experimental study showed that PRGF exerts more potent proliferative and anti-inflammatory effects than AS on a cell culture inflammatory model [ 21 ], although there is not any clinical research in humans comparing both blood products. Similar to PRGF, autologous PRP has been proposed for the treatment of dry eye syndrome with some theoretical advantages.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study

et al. 2017

View full text Add to dashboard Cite

IntroductionThe objective of this study was to evaluate the use of autologous platelet-rich plasma (PRP) eye drops as monotherapy for the treatment of moderate to severe cases of dry eye disease.MethodsThree hundred and sixty-eight patients with moderate to severe dry eye disease (DED) were included in this prospective case series. Subjects were classified as evaporative DED (EDED) or aqueous deficient DED (ADDED). Improvement of the DED subjective symptoms, corneal fluorescein staining (CFS), and corrected distance visual acuity (BCVA) were evaluated. We also analysed how many rounds of PRP therapy were used.ResultsTwo hundred and ninety-seven (80.7%) patients were women, and 71 (19.3%) were men. Two hundred and thirty-two (63%) patients had EDED, while 136 (37%) had ADDED. After 6 weeks of monotherapy treatment with autologous PRP, dry eye symptoms improved in 322 (87.5%) cases. A decrease of CFS was observed in 280 (76.1%) patients. One hundred and six (28.8%) patients improved at least 1 line of BCVA. The scores in the ocular Surface Disease Index and the Oxford scale of corneal fluorescein staining decreased statistically after the treatment (p < 0.05).ConclusionThe topical use of autologous platelet-rich plasma as monotherapy is an effective treatment to improve signs and symptoms in patients suffering from moderate to severe chronic DED.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…PRGF eye drops low cost and easy production and its demonstrated ophthalmic clinical efficacy converts this autologous technology in a new promising human therapy over other hemoderivate products like autologous serum [ 24 – 28 ]. In this way, proteomic characterization of PRGF-treated cells could help to understand regenerative therapy processes and mechanisms and contribute in the optimization of eye drops application and dosage.…”

Section: Introductionmentioning

confidence: 99%

Differential profile of protein expression on human keratocytes treated with autologous serum and plasma rich in growth factors (PRGF)

et al. 2018

View full text Add to dashboard Cite

PurposeThe main objective of this study is to compare the protein expression of human keratocytes treated with Plasma rich in growth factors (PRGF) or autologous serum (AS) and previously induced to myofibroblast by TGF-β1 treatment.MethodsBlood from healthy donor was collected and processed to obtain AS and PRGF eye drops. Blood derivates were aliquoted and stored at -80°C until use. Keratocyte cells were pretreated for 60 minutes with 2.5 ng/ml TGF-β1. After that, cells were treated with PRGF, AS or with TGF-β1 (control). To characterize the proteins deregulated after PRGF and AS treatment, a proteomic approach that combines 1D-SDS–PAGE approach followed by LC–MS/MS was carried out.ResultsResults show a catalogue of key proteins in close contact with a myofibroblastic differentiated phenotype in AS treated-cells, whereas PRGF-treated cells show attenuation on this phenotype. The number of proteins downregulated after PRGF treatment or upregulated in AS-treated cells suggest a close relationship between AS-treated cells and cytoskeletal functions. On the other hand, proteins upregulated after PRGF-treatment or downregulated in AS-treated cells reveal a greater association with processes such as protein synthesis, proliferation and cellular motility.ConclusionThis proteomic analysis helps to understand the molecular events underlying AS and PRGF-driven tissue regeneration processes, providing new evidence that comes along with the modulation of TGF-β1 activity and the reversion of the myofibroblastic phenotype by PRGF.

show abstract

“…(2020) 10:5935 | https://doi.org/10.1038/s41598-020-62407-y www.nature.com/scientificreports www.nature.com/scientificreports/ which are not mechanically rigid to maintain extra augmentations of Schnederian membrane in TSFE sites. Furthermore, although PCs are are known to stimulate proliferation, migration and differentiation of adjacent osteoblasts/fibroblasts, their biodegradation characteristics does not continuously support the elevated Schneiderian membrane [69][70][71] . It is noteworthy that the chamber for bone regeneration at TSFE sites is maintained by the pressed implants and the displaced maxillary bone, thus the non-grafted TSFE is sufficient towards maintaining the vertical bone gain.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic outcomes of non-grafted and platelet concentrations-grafted transcrestal maxillary sinus elevation (TSFE): a systematic review and meta-analysis

Guo

Gulati

Shen

et al. 2020

Sci Rep

View full text Add to dashboard Cite

to evaluate and compare the stability, quantity and quality of bone augmentation at maxillary sinus elevation sites by non-grafted transcrestal sinus floor elevation (TSFE) and platelet concentration grafted transcrestal sinus floor elevation (PC-TSFE). A complete literature search was performed up to April 2019. Clinical controlled trials, retrospective cohort studies, and prospective cohort studies were selected based on inclusion criteria. The clinical outcomes were implant survival rate (ISR), marginal/ crestal bone loss (MBL/CBL) and endo-sinus bone gain (ESBG). Meta-analysis was conducted on these 1-year based values. Furthermore, another meta-analysis on 1-year ISR value was conducted among studies with different residual bone heights (RBH) within the non-grafted TSFE group. A total of 18 studies were included: 13 in TSFE group and 5 in PC-TSFE group. No significant differences were displayed between the 1-year ISR of TSFE (97%, 95%CI = 0.96-0.99) and PC-TSFE group (99%, 95%CI = 0.97-1.00). Among the various studies with different RBH within TSFE group, no significant differences in 1-year ISR were displayed. The 1-year MBL/CBL value of PC-TSFE group (0.73 mm, 95%CI = 0.43-1.13 mm) did not show significant difference as compared to TSFE group (0.60 mm, 95%CI = 0.10-1.10 mm). Furthermore, no significant enhancement was observed on 1-year ESBG value on PC-TSFE group (3.51 mm, 95%CI = 2.31-4.71 mm) in comparison with the TSFE group (2.87 mm, 95%CI = 2.18m-3.55 mm). Grafting platelet concentrations around dental implants at TSFE sites did not significantly enhance the adjacent bone regeneration. Moreover, TSFE was shown to be a reliable therapeutic option for implant sites that need simultaneous maxillary sinus augmentation, even under limited RBH. The maxillary sinus is a cavity of pyramid shape in the maxilla with a volume of 12-15 mL. Its anterior border extends into the premolar roots or distal surface of canine roots, and the posterior border reaches the maxillary tuberosity 1,2. Due to its structure and location, the maxillary sinus sometimes challenges the proper placement of the implant and also compromises its long-term functioning 2. To address this challenge and establish an adequate bone site for implantation, direct (lateral approach) maxillary sinus lift has been suggested since its first introduction in the 1980s 3. That lateral approach is reliable to augment large quantity of bone at surgical sites, however it has strict limitations including excessive surgical trauma and prolonged healing time, which must be addressed 3. In that attempt, transcrestal maxillary sinus elevation (TSFE), which is proceeded via alveolar crest, has been suggested and well implemented in clinical dentistry 4. It compresses and apically pushes the maxillary bone from alveolar crest, and thus elevates maxillary sinus

show abstract

PRGF exerts more potent proliferative and anti-inflammatory effects than autologous serum on a cell culture inflammatory model

Cited by 47 publications

References 43 publications

Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study

Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study

Differential profile of protein expression on human keratocytes treated with autologous serum and plasma rich in growth factors (PRGF)

Therapeutic outcomes of non-grafted and platelet concentrations-grafted transcrestal maxillary sinus elevation (TSFE): a systematic review and meta-analysis

Contact Info

Product

Resources

About